

# Systemic Diseases and Syndromes that Affect the Periodontium

*This chart includes medical conditions known to impact periodontal health and that may be included in a differential diagnosis when periodontitis is detected in pediatric patients. Individualized at-home and professional preventive oral care interventions must be emphasized for these patients. A multidisciplinary approach may be indicated for safe and effective oral health care.*

Disorder	General characteristics	Diagnostic criteria	Oral findings		Treatment considerations
			Clinical	Radiographic	
<b>Chédiak-Higashi syndrome<sup>1,2</sup></b>	<ul style="list-style-type: none"> <li>- Rare autosomal recessive disorder of the immune system</li> <li>- Mild 'atypical' phenotype: 10-15% of cases; 'classic' phenotype: 80-90%, progresses to accelerated phase (fatal without bone marrow transplant)</li> <li>- Characterized by reduced pigmentation, neurological deficits, fever, lymphadenopathy, anemia, neutropenia, hepatosplenomegaly thrombocytopenia.</li> </ul>	<ul style="list-style-type: none"> <li>- Microscopic analysis of WBCs</li> <li>- Genetic testing identifies mutations in the lysosomal trafficking regulator gene (LYST/CHS1)</li> </ul>	<ul style="list-style-type: none"> <li>- Severe gingival inflammation, swelling, and recession</li> <li>- Early onset periodontitis in primary and permanent dentitions</li> <li>- Premature tooth loss</li> <li>- Oral ulcerations may be present</li> </ul>	Alveolar bone loss (localized or generalized)	<ul style="list-style-type: none"> <li>- Immune status and transplantation dictate timing and precautions (e.g., antibiotics)</li> <li>- Supportive management of complications (e.g., antibiotics to treat bacterial infections)</li> <li>- Aggressive recurrent periodontitis may not respond to SRP or antibiotic treatment</li> <li>- For extractions/surgeries, consider adjunctive measures for hemostasis and avoid NSAIDs due to platelet dysfunction</li> <li>- Prosthetic therapy for lost teeth may be considered depending on patient's medical status</li> </ul>
<b>Diabetes mellitus<sup>3,4</sup></b>	<ul style="list-style-type: none"> <li>- Metabolic disorder                             <ul style="list-style-type: none"> <li>• Type 1: autoimmune reaction causes lack of insulin production; usually diagnosed in children and young adults</li> <li>• Type 2: insulin resistance; usually diagnosed in adults</li> <li>• Gestational: insulin resistance during pregnancy</li> </ul> </li> <li>- Associated with increased inflammation, impaired immunologic response and wound healing, CV disease, retinopathy, nephropathy, neuropathy</li> </ul>	<ul style="list-style-type: none"> <li>- Glycated hemoglobin (A1C)</li> <li>- Other tests include: oral glucose tolerance tests, fasting plasma glucose test, random plasma glucose test</li> </ul>	<ul style="list-style-type: none"> <li>- Enlarged, erythematous attached gingiva</li> <li>- Dental/periodontal abscesses</li> <li>- Increased clinical attachment loss and pathologic periodontal pockets</li> <li>- Severe periodontitis</li> </ul>	Alveolar bone loss	<ul style="list-style-type: none"> <li>- Assess level of disease control (e.g., compliance with diet and medications)                             <ul style="list-style-type: none"> <li>• With uncontrolled diabetes, consider antibiotic prophylaxis for invasive oral procedures</li> <li>• Nonsurgical periodontal therapy (e.g., SRP and antimicrobial agents [chlorhexidine, antibiotics]) shows modest glycemic control improvement</li> <li>• Monitor for delayed healing</li> </ul> </li> </ul>
<b>Haim-Munk syndrome<sup>4,5</sup></b>	<ul style="list-style-type: none"> <li>- Rare autosomal recessive syndrome; a phenotypic variant of PLS with mutation to chromosome 11q14-q21 and loss of function of the cathepsin C gene</li> <li>- Milder periodontal disease and more severe dermatologic manifestations than PLS</li> <li>- Clinical manifestations                             <ul style="list-style-type: none"> <li>• Dermatologic: palmo-plantar hyperkeratosis; scaly patches on eyelids, lips, cheeks; skin infections</li> <li>• Skeletal: arachnodactyly, onychogryphosis, acroosteolysis, pes planus, muscle contractures, and destructive arthritis</li> </ul> </li> </ul>	Genetic testing for mutation of cathepsin C gene	<ul style="list-style-type: none"> <li>- Rapidly advancing gingival inflammation and bleeding, deep periodontal pockets, gingival abscesses, periodontal destruction</li> <li>- Premature loss of all primary teeth by age 4-5; loss of permanent teeth by age 16</li> <li>- After tooth loss, gingiva returns to healthy state</li> </ul>	Generalized extensive alveolar bone loss with migration of teeth	<ul style="list-style-type: none"> <li>- Treatment of oral manifestations depends on patient's age, psychological state, and tooth mobility</li> <li>- May include nonsurgical therapy (e.g., monthly SRP, systemic antibiotics) and/or extraction of hopeless teeth</li> <li>- Alveolar loss renders prosthetic rehabilitation challenging</li> </ul>

**Abbreviations in table:** BMI: Body mass index; CDC: Centers for Disease Control and Prevention; CV: cardiovascular; NSAIDs: nonsteroidal anti-inflammatory drugs; PLS: Papillon Lefèvre syndrome; SRP: Scaling and root planing; WBCs: White blood cells.

Disorder	General characteristics	Diagnostic criteria	Oral findings		Treatment considerations
			Clinical	Radiographic	
<b>Hypophosphatasia<sup>6,7</sup></b>	<ul style="list-style-type: none"> <li>- Rare genetic metabolic bone disorder characterized by impaired mineralization of bones and/or teeth</li> <li>- Mutations in the ALPL gene leading to low alkaline phosphatase activity</li> <li>- Wide-ranging severity (involving skeletal, renal, neurological, muscular, respiratory complications); six types based on severity and age of onset</li> <li>- Disturbed cementum formation; tooth loss is one of the first signs of the condition</li> </ul>	<ul style="list-style-type: none"> <li>- Serum alkaline phosphatase (ALP) levels</li> <li>- ALPL gene testing</li> </ul>	<ul style="list-style-type: none"> <li>- Premature exfoliation of primary teeth with little or no root resorption</li> <li>- Clinical inflammation milder than in other systemic diseases associated with periodontitis</li> <li>- Permanent dentition may be clinically normal in mild subtypes or prone to periodontitis and early tooth loss in severe cases</li> </ul>	<ul style="list-style-type: none"> <li>- Alveolar bone loss</li> <li>- Large pulpal chambers and root canals</li> <li>- Thin dentin</li> </ul>	<ul style="list-style-type: none"> <li>- Enzyme replacement therapy, a new disease-modifying treatment, has shown periodontal, tooth, and bone improvements</li> <li>- Caution with orthodontic management due to cementum dysplasia and impaired periodontal attachment</li> <li>- Prosthodontic therapy may include removable prostheses and possible implants to stabilize prosthesis in the permanent dentition for those skeletally mature</li> </ul>
<b>Langerhans cell histiocytosis<sup>8</sup></b>	<ul style="list-style-type: none"> <li>- Rare cancer-like condition (inflammatory myeloid neoplasia) characterized by excessive proliferation/infiltration of histiocytes (Langerhans cells); form categorized as a single-system (single organ affected) or multisystem (several organs affected)</li> <li>- Mortality rate: &lt;10% in single-system vs. 30-50% in multisystem</li> <li>- Average age of onset: 1-3 years; male predilection</li> <li>- Oral manifestations and pain can be the first signs of the condition</li> </ul>	<p>Clinical, microscopic, hematologic, and imaging examinations</p>	<ul style="list-style-type: none"> <li>- Gingivitis, bleeding, recession, mucosal swelling, periodontitis, ulceration</li> <li>- Excessive mobility of teeth, premature exfoliation</li> <li>- Oral pain</li> </ul>	<ul style="list-style-type: none"> <li>- Alveolar bone loss with distinct appearance of teeth floating in soft tissue</li> <li>- Unifocal or multiple lesions within the body of the maxilla and mandible</li> </ul>	<ul style="list-style-type: none"> <li>- Management of periodontal disease is not the first-line of treatment</li> <li>- Treatment of oral lesions depends on the type/extent of disease and may vary from observation to pharmacotherapy, surgical excision/curettage, and/or radiation therapy</li> <li>- Treatment should include basic periodontal therapy and extractions of hopeless teeth depending on immune status</li> </ul>
<b>Leukocyte adhesion deficiency syndromes<sup>4,9</sup></b>	<ul style="list-style-type: none"> <li>- Rare autosomal recessive disorders</li> <li>- Primary immunodeficiency disorder involving both B and T cells</li> <li>- Impaired migration of WBCs to infection sites</li> <li>- Recurrent nonpyogenic bacterial and fungal mucosal infections</li> <li>- Compromised wound healing</li> <li>- Hematopoietic stem cell transplantation is the only curative treatment; high mortality rate</li> </ul>	<ul style="list-style-type: none"> <li>- Elevated WBCs (leukocytosis)</li> <li>- Genetic testing to identify mutations</li> <li>- Flow cytometry analysis to evaluate neutrophil expressions</li> <li>- Key clinical finding: absence of pus at site of infection</li> </ul>	<ul style="list-style-type: none"> <li>- Aggressive and severe gingivitis and rapidly progressive periodontitis</li> <li>- Persistent oral ulcers (gingivostomatitis)</li> <li>- Absence of pus</li> <li>- Premature exfoliation of primary dentition and early loss of permanent teeth</li> </ul>	<p>Alveolar bone loss</p>	<ul style="list-style-type: none"> <li>- Periodontal disease may be refractory to nonsurgical periodontal treatment and rigorous home care regimens</li> <li>- Prompt targeted antibiotic therapy</li> <li>- Adjunctive treatment may include granulocyte/thrombocyte transfusions, recombinant factor VIIa, and intravenous immunoglobulins</li> <li>- Prophylactic antibiotics prior to dental procedures</li> </ul>
<b>Obesity<sup>10</sup></b>	<ul style="list-style-type: none"> <li>- Chronic complex multifactorial metabolic disorder presenting as excessive accumulation of fat</li> <li>- Etiologies: genetic, neuro-endocrine, drug-induced, behavioral (diet and activity)</li> <li>- Comorbidities: diabetes, hypertension, CV disease, obstructive sleep apnea, systemic inflammation, some cancers</li> </ul>	<ul style="list-style-type: none"> <li>- Measured BMI <ul style="list-style-type: none"> <li>• Ages 2-19: ≥95th percentile or ≥30 kg/m<sup>2</sup>, whichever is lower based on age and gender using CDC growth charts</li> <li>• Adult: ≥30 kg/m<sup>2</sup></li> </ul> </li> <li>- Other measures include: waist/hip circumferences, waist to hip ratios</li> </ul>	<ul style="list-style-type: none"> <li>- Increased plaque index, bleeding on probing, periodontal pocket depth, clinical attachment loss</li> <li>- Mouth breathing</li> </ul>	<p>Alveolar bone loss</p>	<ul style="list-style-type: none"> <li>- Comorbidities may influence management</li> <li>- Dietary weight loss may reduce systemic inflammation and, in turn, enhance response to periodontal therapy</li> </ul>

**Abbreviations in table:** BMI: Body mass index; CDC: Centers for Disease Control and Prevention; CV: cardiovascular; NSAIDs: nonsteroidal anti-inflammatory drugs; PLS: Papillon Lefèvre syndrome; SRP: Scaling and root planing; WBCs: White blood cells.

Disorder	General characteristics	Diagnostic criteria	Oral findings		Treatment considerations
			Clinical	Radiographic	
<b>Papillon Lefèvre syndrome (PLS)</b> <sup>11</sup>	<ul style="list-style-type: none"> <li>- Autosomal recessive disorder</li> <li>- Palmoplantar hyperkeratosis, nail dystrophy, pyogenic skin and other infections, intracranial calcification</li> <li>- Rapidly progressing periodontal manifestations beginning shortly after tooth eruption; occurs in primary and permanent dentitions</li> <li>- Etiology: alterations in the CTSC gene and, likely, neutrophil defects</li> </ul>	<ul style="list-style-type: none"> <li>- Urinalysis for cathepsin C activity</li> <li>- Genetic testing for mutation of cathepsin C gene</li> <li>- Key clinical finding: periodontal degeneration</li> </ul>	<ul style="list-style-type: none"> <li>- Rapidly advancing gingival inflammation and bleeding, deep periodontal pockets, gingival abscesses, periodontal destruction</li> <li>- Premature loss of all primary teeth by ages 4-5; loss of permanent teeth by age 16</li> <li>- After tooth loss, gingiva returns to healthy state</li> </ul>	Generalized extensive alveolar bone loss with migration of teeth	<ul style="list-style-type: none"> <li>- Treatment of oral manifestations depends on patient's age, psychological state, and tooth mobility</li> <li>- May include nonsurgical therapy (e.g., monthly SRP, systemic antibiotics) and/or extraction of hopeless teeth</li> <li>- Alveolar loss renders prosthetic rehabilitation challenging</li> </ul>
<b>Periodontal Ehlers-Danlos syndrome</b> <sup>12,13</sup> (Synonyms: Ehlers-Danlos syndrome VIII; pEDS)	<ul style="list-style-type: none"> <li>- One of a group of hereditary connective tissue disorders; autosomal dominant</li> <li>- Characterized by varying features including tissue fragility with easy bruising, vascular complications, joint hypermobility and/or pain, pretibial discoloration/plaques, increased infection rate, hoarse voice</li> <li>- Predominant feature is severe early-onset periodontitis (mean age 14)</li> </ul>	<ul style="list-style-type: none"> <li>- Clinical examination and molecular genetic testing (variant in the genes C1R and C1S which play a role in innate immune system)</li> <li>- Complete lack of gingival attachment is considered pathognomonic</li> <li>- Most children identified through family history</li> </ul>	<ul style="list-style-type: none"> <li>- Severe gingival inflammation, loss of attached gingiva, and gingival thinning and recession</li> <li>- Rapid alveolar bone loss</li> <li>- Premature tooth loss</li> </ul>	Alveolar bone loss	<ul style="list-style-type: none"> <li>- May include nonsurgical therapy (e.g., monthly SRP, systemic antibiotics) and/or extraction of hopeless teeth</li> <li>- Alveolar loss renders prosthetic rehabilitation challenging</li> <li>- Implants at high risk of peri-implantitis</li> </ul>

**Abbreviations in table:** BMI: Body mass index; CDC: Centers for Disease Control and Prevention; CV: cardiovascular; NSAIDs: nonsteroidal anti-inflammatory drugs; PLS: Papillon Lefèvre syndrome; SRP: Scaling and root planing; WBCs: White blood cells.

## References

1. Thumbigere Math V, Rebouças P, Giovani PA, et al. Periodontitis in Chédiak-Higashi syndrome: An altered immunoinflammatory response. *JDR Clin Trans Res* 2018;3(1):35-46. Available at: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734460/". Accessed September 21, 2022.
2. National Organization for Rare Disorders (NORD). Chédiak Higashi Syndrome. Available at: "https://rarediseases.org/rare-diseases/chediak-higashi-syndrome/". Accessed September 1, 2022.
3. American Diabetes Association. Diabetes Overview. Understanding A1c. Diagnosis. Available at: "https://diabetes.org/diabetes/a1c/diagnosis". Accessed September 21, 2022.
4. Albandar JM, Susin C, Hughes FJ. Manifestations of systemic diseases and conditions that affect the periodontal attachment apparatus: Case definitions and diagnostic considerations. *J Periodontol* 2018;89(Suppl 1):S183-S203.
5. National Organization for Rare Disorders (NORD). Haim-Munk Syndrome. Available at: "https://rarediseases.org/rare-diseases/haim-munk-syndrome/". Accessed September 1, 2022.
6. National Organization for Rare Disorders (NORD). Hypophosphatasia. Available at: "https://rarediseases.org/rare-diseases/hypophosphatasia/". Accessed September 1, 2022.
7. Okawa R, Kokomoto K, Nakano K. Dental effects of enzyme replacement therapy in case of childhood-type hypophosphatasia. *BMC Oral Health* 2021;21(1):323.
8. National Organization for Rare Disorders (NORD). Langerhans Cell Histiocytosis. Available at: "https://rarediseases.org/rare-diseases/papillon-lefevre-syndrome/". Accessed September 1, 2022.
9. National Organization for Rare Disorders (NORD). Leukocyte Adhesion Deficiency Syndromes. Available at: "https://rarediseases.org/rare-diseases/leukocyte-adhesion-deficiency-syndromes/". Accessed September 1, 2022.
10. National Collaborative on Childhood Obesity Research. A Guide to Methods for Assessing Childhood Obesity: Overview of Body Composition and Measuring Adiposity. Available at: "https://www.nccor.org/tools-assessingobesity-guide/overview-of-body-composition-and-measuring-adiposity/#two-c". Accessed August 24, 2022.
11. National Organization for Rare Disorders (NORD). Papillon Lefèvre Syndrome. Available at: "https://rarediseases.org/rare-diseases/papillon-lefevre-syndrome/". Accessed August 24, 2022.
12. Kapferer-Seebacher I, van Dijk FS, Zschocke J. Periodontal Ehlers-Danlos Syndrome. In: Adam MP, Everman DB, Mirzaa GM, et al., eds. *GeneReviews*<sup>®</sup> [Internet]. Seattle, Wash.: University of Washington, Seattle; 2021:1993-2022. Available at: "https://www.ncbi.nlm.nih.gov/books/NBK572429/#". Accessed August 24, 2022.
13. Rinner A, Zschocke J, Schossig A, Gröbner R, Strobl H, Kapferer-Seebacher I. High risk of peri-implant disease in periodontal Ehlers-Danlos Syndrome. A case series. *Clin Oral Implants Res* 2018;29:1101-6.